{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:48:25Z","timestamp":1779130105192,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007834","name":"Natural Science Foundation of Ningbo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Bipolar disorder (BD) is predominantly treated with psychotropic drugs, but BD is a complex medical condition and the contribution of psychotropic drugs is not clear. The objectives of this study are: (1) to present psychotropic drugs used in patients with BD; (2) to access changes of psychotropic drug treatments in acute and maintenance episodes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study retrospectively evaluated the medical records of inpatients in the Ningbo Kangning Hospital from January 2019 to December 2019. The medical history of each subject was collected completely, including sociodemographic (gender, age, marital status, and so on) and clinical characteristics at baseline and within 12 months of admission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study ultimately included 204 patients with BD. After 12 months, 73.0% of the patients still took drugs. Mood stabilizers (72\u201390%) and antipsychotics (77\u201395%) were still the most important drugs in patients with BD. Antidepressants (34\u201340%) and benzodiazepines (20\u201334%) were the other frequently used drug classes. For mood stabilizers, 40\u201356% of patients were prescribed lithium. For antipsychotic, 54\u201365% of patients were prescribed quetiapine. Sertraline (6\u20139%) and fluoxetine (5\u20139%) were the antidepressant that most frequently prescribed. Lorazepam (10\u201318%) was the most commonly used benzodiazepine. In psychotropic polypharmacy, the most frequently taken was mood stabilizer plus antipsychotic co-treatment, about 36\u201344% of all patients. A total of 35\u201348% of patients treated by two psychotropic drugs and 24\u201336% received three.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The first 6 months after treatment is very important to medication adherence. Mood stabilizers and antipsychotic remained the primary treatment for BD. Antipsychotic is on the rise in the treatment of BD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1057780","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T06:46:16Z","timestamp":1675752376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A retrospective study of psychotropic drug treatments in bipolar disorder at acute and maintenance episodes"],"prefix":"10.3389","volume":"14","author":[{"given":"Pan","family":"Jing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative.","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch Gen Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2017.09.011","article-title":"The economic burden of bipolar I disorder in the United States in 2015.","volume":"226","author":"Cloutier","year":"2018","journal-title":"J Affect Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/acps.12003","article-title":"Occupational disability in bipolar disorder: analysis of predictors of being on severe disablement benefit (PREBIS study data).","volume":"127","author":"Grande","year":"2013","journal-title":"Acta Psychiatr Scand."},{"key":"B4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/bdi.12296","article-title":"Life expectancy in bipolar disorder.","volume":"17","author":"Kessing","year":"2015","journal-title":"Bipolar Disord."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796019000593","article-title":"Prevalence of suicide attempts in bipolar disorder: a systematic review and meta-analysis of observational studies.","volume":"29","author":"Dong","year":"2019","journal-title":"Epidemiol Psychiatr Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neubiorev.2019.07.022","article-title":"Risk factors for suicidality in patients with panic disorder: a systematic review and meta-analysis.","volume":"105","author":"Tietbohl-Santos","year":"2019","journal-title":"Neurosci Biobehav Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","article-title":"Bipolar disorders.","volume":"396","author":"McIntyre","year":"2020","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology.","volume":"30","author":"Goodwin","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian network for mood and anxiety treatments (CANMAT) and International society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"B10","year":"2018","journal-title":"Bipolar disorder: the NICE guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/15622975.2017.1384850","article-title":"The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder.","volume":"19","author":"Grunze","year":"2018","journal-title":"World J Biol Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5694\/mja17.00658","article-title":"Royal australian and new zealand college of psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary.","volume":"208","author":"Malhi","year":"2018","journal-title":"Med J Aust."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2147\/NDT.S306458","article-title":"A retrospective study of the effects of psychotropic drugs on neuroendocrine hormones in patients with bipolar disorder.","volume":"17","author":"Zhao","year":"2021","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jad.2018.09.027","article-title":"Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression.","volume":"243","author":"Rosenblat","year":"2019","journal-title":"J Affect Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1517\/14740338.2015.1053457","article-title":"Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis.","volume":"14","author":"Galling","year":"2015","journal-title":"Exp Opin Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40263-014-0197-8","article-title":"Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination\/augmentation therapy versus monotherapy.","volume":"28","author":"Ogawa","year":"2014","journal-title":"CNS Drugs."},{"key":"B17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/j.1399-5618.2006.00371.x","article-title":"Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials.","volume":"8","author":"Singh","year":"2006","journal-title":"Bipolar Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/JCP.0000000000000175","article-title":"Pattern of pharmacotherapy by episode types for patients with bipolar disorders and its concordance with treatment guidelines.","volume":"34","author":"Baek","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008341","article-title":"Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study.","volume":"5","author":"Patel","year":"2015","journal-title":"BMJ Open."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e561","DOI":"10.4088\/JCP.10m06504","article-title":"Clinical expression of bipolar disorder type I as a function of age and polarity at onset: convergent findings in samples from France and the United States.","volume":"73","author":"Etain","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0165-0327(01)00432-3","article-title":"The stanley foundation bipolar treatment outcome network: II. Demographics and illness characteristics of the first 261 patients.","volume":"67","author":"Suppes","year":"2001","journal-title":"J Affect Disord."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1509-6","article-title":"Do some anxiety disorders belong to the prodrome of bipolar disorder? A clinical study combining retrospective and prospective methods to analyse the relationship between anxiety disorder and bipolar disorder from the perspective of biorhythms.","volume":"17","author":"Du","year":"2017","journal-title":"BMC Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1192\/bjp.2019.16","article-title":"Changes in prescribing for bipolar disorder between 2009 and 2016: national-level data linkage study in Scotland.","volume":"215","author":"Lyall","year":"2019","journal-title":"Br J Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227217","article-title":"Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study.","volume":"15","author":"Woo","year":"2020","journal-title":"PLoS One."},{"key":"B25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.4088\/JCP.15cs09841","article-title":"Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for clinicians.","volume":"77","author":"Ostacher","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bdi.12234","article-title":"Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study.","volume":"17","author":"Carlborg","year":"2015","journal-title":"Bipolar Disord."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.09m00883yel","article-title":"Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey.","volume":"5","author":"Bates","year":"2010","journal-title":"Prim Care Companion J Clin Psychiatry."},{"key":"B28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1399-5618.2006.00314.x","article-title":"Treatment adherence with antipsychotic medications in bipolar disorder.","volume":"8","author":"Sajatovic","year":"2006","journal-title":"Bipolar Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40263-016-0368-x","article-title":"Medication adherence in patients with bipolar disorder: A comprehensive review.","volume":"30","author":"Levin","year":"2016","journal-title":"CNS Drugs."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/2194-7511-1-5","article-title":"Drug treatment patterns in bipolar disorder: analysis of long-term self-reported data.","volume":"1","author":"Bauer","year":"2013","journal-title":"Int J Bipolar Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13651500510029200","article-title":"Use of polypharmacy and self-reported mood in outpatients with bipolar disorder.","volume":"9","author":"Adli","year":"2005","journal-title":"Int J Psychiatry Clin Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.4088\/JCP.17m11765","article-title":"Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder.","volume":"3","author":"Williams","year":"2018","journal-title":"J Clin Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02967-5","article-title":"Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder.","volume":"20","author":"Tokumitsu","year":"2020","journal-title":"BMC Psychiatry."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/0004867420969819","article-title":"The effect of concomitant benzodiazepine use on neurocognition in stable, long-term patients with bipolar disorder.","volume":"55","author":"Ca\u00f1ada","year":"2020","journal-title":"Aust N Z J Psychiatry."},{"key":"B36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","article-title":"Management of benzodiazepine misuse and dependence.","volume":"5","author":"Brett","year":"2015","journal-title":"Aust Prescr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jad.2016.01.043","article-title":"Changes in mood stabilizer prescription patterns in bipolar disorder.","volume":"195","author":"Karanti","year":"2016","journal-title":"J Affect Disord."},{"key":"B38","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.clinthera.2009.04.022","article-title":"Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: A retrospective claims database analysis.","volume":"4","author":"Kim","year":"2009","journal-title":"Clin Ther."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2019.104511","article-title":"Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder.","volume":"112","author":"Nestsiarovich","year":"2019","journal-title":"Psychoneuroendocrinology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tins.2017.10.006","article-title":"The emerging neurobiology of bipolar disorder.","volume":"41","author":"Harrison","year":"2018","journal-title":"Trends Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1176\/appi.ps.201200529","article-title":"Psychotropic polypharmacy for the treatment of bipolar disorder in Taiwan.","volume":"65","author":"Hung","year":"2014","journal-title":"Psychiatr Serv."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry.","volume":"67","author":"Mojtabai","year":"2010","journal-title":"Arch Gen Psychiatry."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1057780\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T13:40:58Z","timestamp":1675777258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1057780\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":42,"alternative-id":["10.3389\/fpsyt.2023.1057780"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1057780","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"article-number":"1057780"}}